Insulin resistance and cardiovascular diseases: focus on common in pathogenesis and treatment

Posted on by adminLeave a comment

Prof. Zhuravlyova L.V., asst. Rohachova T.A., assoc. prof. Sokolnikova N.V., assoc. prof. Yankevich O.O.

Kharkiv National Medical University

Department of Internal Medicine №3 and Endocrinology

The prevalence of cardiovascular disease and type 2 diabetes has increased dramatically worldwide over the past 30 years. These diseases have become a worldwide epidemic and the main cause of disability and premature death. The reasons for these negative trends are the wide distribution of improper nutrition, sedentary lifestyle, smoking, lack of sleep, which lead to the development of insulin resistance. Insulin resistance underlies the development of multiple metabolic disorders: hyperinsulinemia, hyperglycemia, proatherogenic dyslipidemia, and inflammation, which lead to cardiovascular disease and type 2 diabetes. With this in mind, scientists and medical professionals should focus on the development and implementation of effective methods for the prevention and treatment of insulin resistance. An important tasks are the implementation of a healthy lifestyle, namely proper nutrition and regular physical activity, the use of pharmacological drugs that improve cardiovascular risk factors. However, there remains a need for further research and improvement of these treatment methods, as well as the development of new methods of prevention and treatment of cardiovascular diseases and type 2 diabetes.

Key words: cardiovascular diseases, diabetes type 2, insulin resistance, hyperinsulinemia, hyperglycemia, proatherogenic dyslipidemia, inflammation

https://doi.org/10.15407/internalmed2023.02.046

Download.PDF (ukr)

Cite:

  1. Журавльова, Л.В. Інсулінорезистентність і серцево-судинні захворювання: фокус на спільне в патогенезі і лікуванні / Л.В. Журавльова, Т.А. Рогачова, Н.В. Сокольнікова, О.О. Янкевич // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2023. – № 2. – С. 46-54. http://doi.org/10.15407/internalmed2023.02.046
  2. Zhuravlyova LV, Rohachova TA, Sokolnikova NV, Yankevich OO.  [Insulin resistance and cardiovascular diseases: focus on common in pathogenesis and treatment]. Shidnoevr. z. vnutr. simejnoi med. 2023;2:46-54. Ukrainian. http://doi.org/10.15407/internalmed2023.02.046

References:

  1. ElSayed N. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46 (1):19–40.
  2. Mazibuko-Mbeje S, Dludla P, Nkambule B, Obonye N, Louw J. The Role of Glucose and Fatty Acid Metabolism in the Development of Insulin Resistance in Skeletal Muscle. Muscle Cell and Tissue – Current Status of Research Field. 2018;:. http://dx.doi.org/10.5772/intechopen.75904
  3. Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T, Nozaki E. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart and Vessels. 2018;34(6):916-925. http://dx.doi.org/10.1007/s00380-018-1319-x
  4. Perkins J, Joy N, Tate D, Davis S. Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans. American Journal of Physiology-Endocrinology and Metabolism. 2015;309(2):E168-E176. http://dx.doi.org/10.1152/ajpendo.00064.2015
  5. Chandel S, Sathis A, Dhar M, Giri H, Nathan A, Samawar S, Gupta A, Gopal J, Harish R, Mohan V, Dixit M. Hyperinsulinemia promotes endothelial inflammation via increased expression and release of Angiopoietin-2. Atherosclerosis. 2020;307:1-10. http://dx.doi.org/10.1016/j.atherosclerosis.2020.06.016
  6. Fiaschi T, Magherini F, Gamberi T, Lucchese G, Faggian G, Modesti A, Modesti P. Hyperglycemia and angiotensin II cooperate to enhance collagen I deposition by cardiac fibroblasts through a ROS-STAT3-dependent mechanism. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. 2014;1843(11):2603-2610. http://dx.doi.org/10.1016/j.bbamcr.2014.07.009
  7. Goossens G. The Renin-Angiotensin System in the Pathophysiology of Type 2 Diabetes. Obesity Facts. 2012;5(4):611-624. http://dx.doi.org/10.1159/000342776
  8. Hsueh W, Wyne K. Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension. The Journal of Clinical Hypertension. 2011;13(4):224-237. http://dx.doi.org/10.1111/j.1751-7176.2011.00449.x
  9. Sasaki N, Maeda R, Ozono R, Nakano Y, Higashi Y. Association of obesity with serum free fatty acid levels in individuals at different stages of prediabetes. Clinical Obesity. 2021;12(1):. http://dx.doi.org/10.1111/cob.12496
  10. Zhang H, Zhao X, Guo Y, Zhu C, Wu N, Sun J, Liu G, Dong Q, Li J. Free fatty acids and cardiovascular outcome: a Chinese cohort study on stable coronary artery disease. Nutrition amp; Metabolism. 2017;14(1):. http://dx.doi.org/10.1186/s12986-017-0195-1
  11. Zhang M, Cao Y, Wu L, Guo N, Hou B, Sun L, Guo Y, Wu N, Dong Q, Li J. Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. BMC Endocrine Disorders. 2020;20(1):. http://dx.doi.org/10.1186/s12902-020-00636-y
  12. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga F. Association between insulin resistance and the development of cardiovascular disease. Cardiovascular Diabetology. 2018;17(1):. http://dx.doi.org/10.1186/s12933-018-0762-4
  13. Adeva-Andany M, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(2):1449-1455. http://dx.doi.org/10.1016/j.dsx.2019.02.023
  14. Tanaka A, Imai T, Shimabukuro M, Taguchi I, Sezai A, Toyoda S, Watada H, Ako J, Node K. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial. Cardiovascular Diabetology. 2022;21(1):. http://dx.doi.org/10.1186/s12933-022-01589-3
  15. Su C, Xue J, Ye C, Chen A. Role of the central renin‑angiotensin system in hypertension (Review). International Journal of Molecular Medicine. 2021;47(6):. http://dx.doi.org/10.3892/ijmm.2021.4928
  16. Jin X, Qiu T, Li L, Yu R, Chen X, Li C, Proud C, Jiang T. Pathophysiology of obesity and its associated diseases. Acta Pharmaceutica Sinica B. 2023;13(6):2403-2424. http://dx.doi.org/10.1016/j.apsb.2023.01.012
  17. Correction to: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):. http://dx.doi.org/10.1161/cir.0000000000000725
  18. DiNicolantonio J, OKeefe J. Added sugars drive coronary heart disease via insulin resistance and hyperinsulinaemia: a new paradigm. Open Heart. 2017;4(2):e000729. http://dx.doi.org/10.1136/openhrt-2017-000729
  19. Lin W. A large-scale observational study linking various kinds of physical exercise to lipoprotein-lipid profile. Journal of the International Society of Sports Nutrition. 2021;18(1):. http://dx.doi.org/10.1186/s12970-021-00436-2
  20. Franczyk B, Gluba-Brzózka A, Ciałkowska-Rysz A, Ławiński J, Rysz J. The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review. International Journal of Molecular Sciences. 2023;24(5):4653. http://dx.doi.org/10.3390/ijms24054653
  21. Muscella A, Stefàno E, Marsigliante S. The effects of exercise training on lipid metabolism and coronary heart disease. American Journal of Physiology-Heart and Circulatory Physiology. 2020;319(1):H76-H88. http://dx.doi.org/10.1152/ajpheart.00708.2019
  22. Hayes P, Ferrara A, Keating A, McKnight K, O’Regan A. Physical Activity and Hypertension. Reviews in Cardiovascular Medicine. 2022;23(9):302. http://dx.doi.org/10.31083/j.rcm2309302
  23. Ferretti P, Wanner S. Effectiveness of regular physical activity in preventing the progression of arterial hypertension: improved cardiovascular autonomic control during sleep. Hypertension Research. 2022;45(7):1213-1216. http://dx.doi.org/10.1038/s41440-022-00942-z
  24. Egan B. Physical Activity and Hypertension. Hypertension. 2017;69(3):404-406. http://dx.doi.org/10.1161/hypertensionaha.116.08508
  25. Korsager Larsen M, Matchkov V. Hypertension and physical exercise: The role of oxidative stress. Medicina. 2016;52(1):19-27. http://dx.doi.org/10.1016/j.medici.2016.01.005
  26. Dassanayake S, Sole G, Wilkins G, Gray E, Skinner M. Effectiveness of Physical Activity and Exercise on Ambulatory Blood Pressure in Adults with Resistant Hypertension: A Systematic Review and Meta-Analysis. High Blood Pressure & Cardiovascular Prevention. 2022;29(3):275-286. http://dx.doi.org/10.1007/s40292-022-00517-6
  27. Iaccarino G, Franco D, Sorriento D, Strisciuglio T, Barbato E, Morisco C. Modulation of Insulin Sensitivity by Exercise Training: Implications for Cardiovascular Prevention. Journal of Cardiovascular Translational Research. 2020;14(2):256-270. http://dx.doi.org/10.1007/s12265-020-10057-w
  28. Bird S, Hawley J. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport & Exercise Medicine. 2017;2(1):e000143. http://dx.doi.org/10.1136/bmjsem-2016-000143
  29. Amador M, Meza C, McAinch A, King G, Covington J, Bajpeyi S. Exercise-Induced Improvements in Insulin Sensitivity Are Not Attenuated by a Family History of Type 2 Diabetes. Frontiers in Endocrinology. 2020;11:. http://dx.doi.org/10.3389/fendo.2020.00120
  30. Sjøberg K, Frøsig C, Kjøbsted R, Sylow L, Kleinert M, Betik A, Shaw C, Kiens B, Wojtaszewski J, Rattigan S, Richter E, McConell G. Exercise Increases Human Skeletal Muscle Insulin Sensitivity via Coordinated Increases in Microvascular Perfusion and Molecular Signaling. Diabetes. 2017;66(6):1501-1510. http://dx.doi.org/10.2337/db16-1327
  31. DiMenna F, Arad A. Exercise as ‘precision medicine’ for insulin resistance and its progression to type 2 diabetes: a research review. BMC Sports Science, Medicine and Rehabilitation. 2018;10(1):. http://dx.doi.org/10.1186/s13102-018-0110-8
  32. Cho S, Jeong S, Shin J, Park S, Jang S. Short-term smoking increases the risk of insulin resistance. Scientific Reports. 2022;12(1):. http://dx.doi.org/10.1038/s41598-022-07626-1
  33. Artese A, Stamford B, Moffatt R. Cigarette Smoking: An Accessory to the Development of Insulin Resistance. American Journal of Lifestyle Medicine. 2017;13(6):602-605. http://dx.doi.org/10.1177/1559827617726516
  34. Wang J, Gao Y, Duan L, Wei S, Liu J, Tian L, Quan J, Zhang Q, Liu J, Yang J. Metformin ameliorates skeletal muscle insulin resistance by inhibiting miR-21 expression in a high-fat dietary rat model. Oncotarget. 2017;8(58):98029-98039. http://dx.doi.org/10.18632/oncotarget.20442
  35. Yang Y, Liao Z, Xiao Q. Metformin ameliorates skeletal muscle atrophy in Grx1 KO mice by regulating intramuscular lipid accumulation and glucose utilization. Biochemical and Biophysical Research Communications. 2020;533(4):1226-1232. http://dx.doi.org/10.1016/j.bbrc.2020.09.119
  36. Bradley E, Premilovac D, Betik A, Hu D, Attrill E, Richards S, Rattigan S, Keske M. Metformin improves vascular and metabolic insulin action in insulin-resistant muscle. Journal of Endocrinology. 2019;243(2):85-96. http://dx.doi.org/10.1530/joe-19-0067
  37. Adachi H, Nakano H, Yamamoto K, Nakata M, Bekki H, Honma T, Yoshiyama H, Nohara M. Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia. Lipids in Health and Disease. 2015;14(1):. http://dx.doi.org/10.1186/1476-511x-14-1
  38. Ohbu‐Murayama K, Adachi H, Hirai Y, Enomoto M, Fukami A, Obuchi A, Yoshimura A, Nakamura S, Nohara Y, Nakao E, Umeki Y, Fukumoto Y. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. Journal of Diabetes Investigation. 2014;6(3):325-333. http://dx.doi.org/10.1111/jdi.12298
  39. Di Pino A, DeFronzo R. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews. 2019;40(6):1447-1467. http://dx.doi.org/10.1210/er.2018-00141
  40. Das U. Renin–angiotensin–aldosterone system in insulin resistance and metabolic syndrome. Journal of Translational Internal Medicine. 2016;4(2):66-72. http://dx.doi.org/10.1515/jtim-2016-0022
  41. Favre G, Esnault V, Van Obberghen E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. American Journal of Physiology-Endocrinology and Metabolism. 2015;308(6):E435-E449. http://dx.doi.org/10.1152/ajpendo.00391.2014
  42. Nurun Nabi A, Ebihara A. Diabetes and Renin-Angiotensin-Aldosterone System: Pathophysiology and Genetics. Renin-Angiotensin Aldosterone System. 2021;:. http://dx.doi.org/10.5772/intechopen.97518
  43. Buscemi S, Buscemi C, Borzì A, Cosentino L, Rosafio G, Randazzo C, Colomba D, Di Raimondo D, Pluchinotta F, Parrinello G. Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study). Metabolic Syndrome and Related Disorders. 2020;18(2):110-118. http://dx.doi.org/10.1089/met.2019.0099
  44. Hall J, Eurich D, Nagy D, Tjosvold L, Gamble J. Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials. Journal of General Internal Medicine. 2020;35(6):1849-1860. http://dx.doi.org/10.1007/s11606-020-05731-3
  45. Lepenies J, Wigger L, Gruber S. Spironolactone may worsen glucose control in patients with type 2 diabetes mellitus and systolic hypertension. J Diabetes Complications. 2016;30 (3):456–461. doi: 10.1016/j. jdiacomp.2015.12.008.
  46. Rizos C. Antihypertensive drugs and glucose metabolism. World Journal of Cardiology. 2014;6(7):517. http://dx.doi.org/10.4330/wjc.v6.i7.517